Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab After Radiotherapy for Oligometastatic NPC
NCT04221516Phase 2Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jan 2020
- Primary completion
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in nasopharyngeal carcinoma (NPC), sponsored by Nanfang Hospital, Southern Medical University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04221516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221516.